# ATP1B1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ATP1B1 encodes the regulatory β1 subunit of the ubiquitous Na⁺/K⁺-ATPase, crucial for maintaining electrochemical gradients, cell volume, and membrane potential, with critical roles in renal fluid balance and alveolar fluid clearance.
- Beyond ion transport, ATP1B1 functions as a cell adhesion molecule via its immunoglobulin-like ectodomain, contributing to epithelial barrier integrity and acting as a tumor suppressor in epithelial cancers by inhibiting motility and EMT.
- ATP1B1 is a key regulator of innate antiviral immunity, induced by viral infections to enhance type I interferon production through TRAF3/TRAF6 ubiquitination, independent of its ion-pumping activity.
- Dysregulation of ATP1B1, through promoter hypermethylation (e.g., in ccRCC) or copy number amplification (e.g., in DLBCL), is implicated in various pathologies, with context-dependent roles in cancer progression and prognosis.
- Germline polymorphisms in ATP1B1, particularly in the 3' UTR affecting alternative polyadenylation, are associated with essential hypertension, linking its post-transcriptional regulation to blood pressure control.
- The Na⁺/K⁺-ATPase holoenzyme, including ATP1B1, is the target of cardiac glycosides, and ATP1B1's isoform composition influences cellular sensitivity to these drugs and palytoxin.

---

## Executive Summary & Key Metadata

The **ATP1B1** gene encodes the β1 subunit of the Na⁺/K⁺-ATPase (sodium-potassium adenosine triphosphatase), a ubiquitous and essential plasma membrane enzyme complex that maintains electrochemical gradients across cell membranes. This heterodimeric pump, composed of a catalytic α subunit and a regulatory β subunit, is fundamental to numerous physiological processes, including ion homeostasis, secondary active transport, cell volume regulation, and membrane potential establishment. Beyond its canonical ion-pumping function, ATP1B1 has emerged as a critical regulator of cell adhesion, epithelial barrier integrity, signal transduction, and innate immune responses. Its dysregulation—through epigenetic silencing, copy number alterations, or structural rearrangements—has been implicated in a spectrum of human pathologies, ranging from hypertension and renal dysfunction to aggressive malignancies and viral infections.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | ATP1B1 |
| **UniProt Accession** | P05026 |
| **Representative PDB ID** | true (multiple structures of Na⁺/K⁺-ATPase holoenzyme available, e.g., 3B8E, 4HYC) |
| **Chromosomal Locus** | 1q24.2 (GRCh38: chr1:169,106,515–169,132,705, minus strand) |
| **Primary Molecular Function** | Regulatory β subunit of Na⁺/K⁺-ATPase; ion transport, cell adhesion, signal transduction |
| **Disease & Pathology Associations** | Essential hypertension, clear cell renal cell carcinoma (ccRCC), diffuse large B-cell lymphoma (DLBCL), gastric cancer, breast cancer, hepatocellular carcinoma, viral infections (HCMV), congenital disorders of glycosylation (secondary) |
| **Key Isoforms** | Multiple transcript variants via alternative splicing and alternative polyadenylation |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *ATP1B1* gene is located on the long arm of chromosome 1 at cytogenetic band **1q24.2**. The reference genome assembly (GRCh38/hg38) places the gene between coordinates chr1:169,106,515 and chr1:169,132,705 on the minus (reverse) strand. The gene spans approximately **26.2 kilobases (kb)** of genomic DNA and contains **7 exons** and **6 introns**, with the translation start site located in exon 1 and the stop codon in exon 7. The gene structure is highly conserved across vertebrates, reflecting its fundamental physiological importance. Early linkage studies in porcine models mapped *ATP1B1* to chromosome 4, demonstrating conserved synteny with human chromosome 1q.

The promoter region of *ATP1B1* lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for ubiquitous transcription factors, including Sp1, AP-1, and CREB. The 5' untranslated region (UTR) is relatively short (~100–200 bp), while the 3' UTR is notably longer and contains multiple regulatory elements, including AU-rich elements and a polymorphic T-rich sequence (TRS) that modulates alternative polyadenylation. This 3' UTR architecture is critical for post-transcriptional regulation, as differential polyadenylation site usage produces transcripts with varying 3' UTR lengths, which in turn affects mRNA stability, localization, and translational efficiency.

### 1.2 Promoter Architecture and Epigenetic Regulation

The *ATP1B1* promoter is embedded within a CpG island that spans the first exon and extends into the proximal promoter region. This CpG island is a major target for epigenetic regulation, particularly DNA methylation. In clear cell renal cell carcinoma (ccRCC), hypermethylation of the *ATP1B1* promoter CpG island leads to transcriptional silencing, contributing to tumor progression. Selvakumar et al. demonstrated that treatment of ccRCC cell lines with the demethylating agent 5-aza-2'-deoxycytidine restored *ATP1B1* expression, confirming that promoter methylation is a primary mechanism of gene silencing in this malignancy. Similarly, in a rat model of maternal protein restriction, postnatal nutritional environment was shown to reprogram renal DNA methylation patterns, with *ATP1B1* among the differentially methylated genes, suggesting that early-life nutrition can have lasting effects on *ATP1B1* expression and renal function.

Histone modifications also play a role in *ATP1B1* regulation. In alveolar epithelial cells, transforming growth factor-β (TGF-β) downregulates Na⁺/K⁺-ATPase function through histone deacetylase (HDAC)-dependent mechanisms, reducing *ATP1B1* expression and impairing alveolar fluid clearance. This epigenetic control is particularly relevant in acute lung injury and pulmonary edema, where maintaining alveolar fluid homeostasis is critical.

### 1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation (ChIP) studies and promoter-reporter assays have identified several cis-regulatory elements within the *ATP1B1* promoter. The transcription factor **CREB (cAMP response element-binding protein)** binds to a cAMP response element (CRE) located approximately 200 bp upstream of the transcription start site. CREB-regulated transcriptional coactivators (CRTCs) interact with CREB to enhance *ATP1B1* transcription in renal proximal tubule cells, linking hormonal signaling (e.g., parathyroid hormone, dopamine) to Na⁺/K⁺-ATPase expression. Salt-inducible kinase 1 (SIK1) negatively regulates this pathway by phosphorylating CRTCs, promoting their cytoplasmic sequestration and degradation, thereby reducing *ATP1B1* transcription. This CREB/CRTC/SIK1 regulatory axis represents a key mechanism for long-term control of Na⁺/K⁺-ATPase abundance in response to salt intake and hormonal stimuli.

Additional transcription factor binding sites include those for **Sp1**, **AP-1**, and **NF-κB**. The NF-κB binding site is particularly relevant to the gene's role in innate immunity, as inflammatory cytokines can induce *ATP1B1* expression through this pathway. Progesterone receptor (PR) signaling also directly regulates *ATP1B1* in breast cancer cells, where PR binding to the promoter region modulates gene expression in response to progestins.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *ATP1B1* generates multiple transcript variants. The predominant transcript encodes the full-length β1 subunit of 303 amino acids. However, several minor splice variants have been documented:

- **Variant 1 (canonical)**: Encodes the full-length protein (303 aa), including the N-terminal cytoplasmic domain, single transmembrane helix, and large C-terminal ectodomain.
- **Variant 2**: Uses an alternative splice acceptor site in exon 4, resulting in an in-frame deletion of 9 amino acids in the ectodomain. This variant retains ion transport function but may have altered glycosylation patterns.
- **Variant 3**: Retains intron 5, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role in modulating ATP1B1 expression levels.

Alternative polyadenylation (APA) is a major source of transcript diversity. The 3' UTR of *ATP1B1* contains a polymorphic T-rich sequence (TRS) that influences polyadenylation site choice. Prasad et al. demonstrated that variation in this TRS element is associated with differential use of proximal versus distal polyadenylation signals, leading to transcripts with short or long 3' UTRs. The long 3' UTR isoform contains additional microRNA binding sites and is subject to more extensive post-transcriptional regulation. Importantly, this polymorphism is associated with blood pressure variation in human populations, linking APA regulation to hypertension susceptibility.

### 1.5 Cross-Species Conservation and Synteny

*ATP1B1* is highly conserved across metazoans. The porcine ortholog maps to chromosome 4, and linkage analysis has established conserved synteny with human chromosome 1q. In chickens, *ATP1B1* expression in the uterus is associated with eggshell strength, highlighting its role in epithelial ion transport across species. In treefrogs, *ATP1B1* is among the genes mediating local adaptation to salt-tolerant environments, underscoring its evolutionary significance in osmoregulation. The gene's presence in all vertebrate genomes examined, coupled with its conserved intron-exon structure, indicates strong purifying selection and essential function.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The ATP1B1 protein (UniProt P05026) is a type II transmembrane glycoprotein of **303 amino acids** with a molecular weight of approximately **35 kDa** for the core polypeptide, and **40–60 kDa** after N-linked glycosylation. The protein is organized into three distinct structural domains:

1. **N-terminal cytoplasmic domain (residues 1–34)**: A short, hydrophilic segment that extends into the cytoplasm. This domain contains a conserved motif (residues 24–29, **KRRKRR**) that mediates interactions with the α subunit and is essential for assembly of the α/β heterodimer. The cytoplasmic tail also contains phosphorylation sites that may modulate protein-protein interactions.

2. **Transmembrane domain (residues 35–65)**: A single hydrophobic α-helix that anchors the protein in the plasma membrane. This domain contains a conserved **GXXXG** motif that facilitates helix-helix packing with the α subunit's transmembrane helices. The transmembrane domain is critical for the structural integrity of the holoenzyme and for proper membrane targeting.

3. **C-terminal ectodomain (residues 66–303)**: A large, highly structured extracellular domain that is the most conserved region of the protein. This domain contains:
   - **Six conserved cysteine residues** (Cys⁸⁶, Cys¹²⁶, Cys¹⁵⁸, Cys¹⁷⁵, Cys²⁰⁴, Cys²⁷⁵) that form three disulfide bonds, stabilizing the immunoglobulin-like fold.
   - **Three N-linked glycosylation sites** (Asn¹¹⁵, Asn¹⁵⁸, Asn¹⁹³) that are essential for proper protein folding, trafficking, and cell surface expression.
   - An **immunoglobulin-like (Ig-like) domain** fold, which is structurally homologous to the extracellular domains of cell adhesion molecules. This structural similarity underlies ATP1B1's role in cell-cell adhesion.

### 2.2 Quaternary Structure and Holoenzyme Assembly

ATP1B1 functions as an obligate subunit of the Na⁺/K⁺-ATPase holoenzyme, which is a heterodimer (or higher-order oligomer) composed of:

- **α subunit** (catalytic): Encoded by *ATP1A1–ATP1A4* genes. The α subunit contains the ion binding sites, ATP binding site, and phosphorylation domain. It has 10 transmembrane helices and large cytoplasmic loops.
- **β subunit** (regulatory): Encoded by *ATP1B1–ATP1B3* genes. The β subunit is required for:
  - Proper folding and ER export of the α subunit
  - Plasma membrane targeting and stabilization
  - Modulation of ion transport kinetics (K⁺ affinity)
  - Cell adhesion functions independent of ion transport

The α/β interaction is mediated primarily through the transmembrane domains and the extracellular loops. The β subunit's ectodomain wraps around the α subunit's extracellular loops, forming an extensive interface. Cryo-electron microscopy (cryo-EM) and X-ray crystallography structures of the Na⁺/K⁺-ATPase holoenzyme (e.g., PDB: 3B8E, 4HYC) reveal that the β1 ectodomain forms a seven-stranded β-sandwich (Ig-like fold) that contacts the α subunit's extracellular domains M7-M8 loop and M9-M10 loop. This interaction is essential for the structural integrity of the pump and for its proper function.

### 2.3 Structural Dynamics and Conformational States

The Na⁺/K⁺-ATPase undergoes large conformational changes during the transport cycle, alternating between E1 (ions bound intracellularly, high ATP affinity) and E2 (ions bound extracellularly, low ATP affinity) states. The β subunit is not directly involved in ion translocation but stabilizes the E2 conformation and modulates the apparent affinity for K⁺. Molecular dynamics simulations suggest that the β subunit's ectodomain undergoes subtle conformational rearrangements during the E1→E2 transition, which may influence the gating of the ion translocation pathway.

The three disulfide bonds in the ectodomain are critical for maintaining the folded state. Reduction of these bonds leads to protein misfolding, ER retention, and degradation via the ubiquitin-proteasome pathway. The N-linked glycans, particularly the complex-type glycans added in the Golgi, are essential for cell surface expression and for interactions with lectin-like molecules on adjacent cells.

### 2.4 Structural Basis for Cell Adhesion Function

The Ig-like fold of the ATP1B1 ectodomain is structurally homologous to the extracellular domains of the L1 family of cell adhesion molecules (e.g., NCAM, L1CAM). This structural similarity enables ATP1B1 to participate in homophilic and heterophilic cell-cell interactions. Specifically, ATP1B1 can bind to itself (homophilic adhesion) on adjacent cells, contributing to cell-cell adhesion and epithelial barrier formation. It can also interact with other adhesion molecules, including E-cadherin, modulating adherens junction stability.

In epithelial cells, ATP1B1 is localized to the basolateral membrane, where it co-localizes with E-cadherin at adherens junctions. Downregulation of ATP1B1 in cancer cells leads to loss of cell adhesion, increased cell motility, and epithelial-mesenchymal transition (EMT). The adhesion function of ATP1B1 is independent of its ion transport activity, as demonstrated by experiments showing that ATP1B1 mutants lacking ion transport function can still support cell adhesion.

### 2.5 Interactive 3D Visualization

For a comprehensive structural analysis, the interactive 3D protein visualizer provides a dynamic view of ATP1B1 within the context of the full Na⁺/K⁺-ATPase complex. Users can explore domain architecture, identify key residues, and examine the α/β interface.

[Interactive 3D Protein Visualizer: Load ATP1B1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P05026)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Ion Transport Function

The primary function of ATP1B1 is to serve as the regulatory subunit of the Na⁺/K⁺-ATPase, which actively transports three Na⁺ ions out of the cell and two K⁺ ions into the cell per ATP hydrolyzed. This electrogenic exchange generates and maintains the electrochemical gradients that are essential for:

- **Resting membrane potential**: The Na⁺/K⁺-ATPase contributes directly to the negative resting membrane potential by exporting more positive charge than it imports.
- **Secondary active transport**: The Na⁺ gradient drives numerous secondary transporters, including Na⁺/glucose cotransporters (SGLT), Na⁺/Ca²⁺ exchangers (NCX), and Na⁺/H⁺ exchangers (NHE).
- **Cell volume regulation**: The pump's activity counteracts osmotic swelling by exporting Na⁺ and importing K⁺.
- **Fluid secretion and absorption**: In epithelial tissues, the basolateral Na⁺/K⁺-ATPase provides the driving force for transcellular fluid movement.

The β1 subunit specifically modulates the pump's affinity for K⁺. Compared to β2 and β3 isoforms, β1 confers higher apparent K⁺ affinity, making the α1β1 isozyme particularly well-suited for tissues with fluctuating extracellular K⁺ concentrations, such as the kidney and lung.

### 3.2 Role in Alveolar Fluid Clearance

In the lung, the Na⁺/K⁺-ATPase expressed on alveolar epithelial type II (ATII) cells is the primary driver of alveolar fluid clearance (AFC). The pump creates an osmotic gradient that drives water reabsorption from the alveolar space into the interstitium. Studies using AT1 cell-specific knockout of *Atp1b1* in mice demonstrated that loss of β1 subunit expression results in significantly impaired AFC, leading to increased lung water content and susceptibility to pulmonary edema. This finding establishes ATP1B1 as a critical determinant of lung fluid homeostasis and a potential therapeutic target for conditions such as acute respiratory distress syndrome (ARDS) and cardiogenic pulmonary edema.

The regulation of *ATP1B1* expression in alveolar epithelial cells is under tight epigenetic control. TGF-β, a key mediator of acute lung injury, downregulates *ATP1B1* expression through HDAC-dependent mechanisms, reducing Na⁺/K⁺-ATPase activity and impairing AFC. HDAC inhibitors, such as trichostatin A, can reverse this effect, suggesting a potential therapeutic strategy for enhancing fluid clearance in injured lungs.

### 3.3 Renal Function and Blood Pressure Regulation

In the kidney, the Na⁺/K⁺-ATPase in the proximal tubule is responsible for the majority of Na⁺ reabsorption, making it a central regulator of blood pressure. The expression of *ATP1B1* in renal proximal tubule cells is controlled by a complex regulatory network involving:

1. **CREB/CRTC pathway**: Parathyroid hormone and dopamine activate the cAMP/PKA pathway, leading to CREB phosphorylation and recruitment of CRTC coactivators, which enhance *ATP1B1* transcription.
2. **SIK1 inhibition**: Salt-inducible kinase 1 phosphorylates CRTCs, promoting their nuclear export and degradation, thereby reducing *ATP1B1* expression.
3. **Prostaglandin signaling**: Prostaglandins, particularly PGE2, modulate Na⁺/K⁺-ATPase activity in the proximal tubule through both transcriptional and post-translational mechanisms.

Genetic variation in *ATP1B1* has been associated with essential hypertension in multiple populations. The polymorphic T-rich sequence (TRS) in the 3' UTR, which regulates alternative polyadenylation, is associated with blood pressure variation. Additionally, single nucleotide polymorphisms (SNPs) in *ATP1B1* have been linked to hypertension in African-American populations and in patients with chronic kidney disease. A study by Ding-liang Zhu identified associations between *ATP1B1* and *RGS5* polymorphisms and essential hypertension, further supporting the gene's role in blood pressure regulation.

### 3.4 Cell Adhesion and Epithelial Barrier Function

Beyond ion transport, ATP1B1 functions as a cell adhesion molecule. The Ig-like ectodomain mediates homophilic interactions between adjacent cells, contributing to the formation and maintenance of epithelial barriers. In polarized epithelial cells, ATP1B1 is localized to the basolateral membrane, where it co-localizes with E-cadherin at adherens junctions. This localization is dependent on the β subunit's cytoplasmic tail, which contains a basolateral sorting signal.

Downregulation of ATP1B1 in cancer cells leads to:
- Loss of cell-cell adhesion
- Increased cell motility and invasion
- Epithelial-mesenchymal transition (EMT)
- Increased metastatic potential

In gastric adenocarcinoma cells (SGC-7901), overexpression of ATP1B1 inhibited cell proliferation and migration, while knockdown had the opposite effect. Similarly, in hepatocellular carcinoma cells, ATP1B1 overexpression suppressed proliferation and invasion. In breast cancer MCF-7 cells, ATP1B1 overexpression enhanced the cytotoxic effects of adriamycin and reversed drug resistance. These findings establish ATP1B1 as a tumor suppressor in multiple cancer types.

### 3.5 Regulation of Innate Immune Responses

Recent studies have revealed a novel role for ATP1B1 in innate immunity. Cao et al. demonstrated that ATP1B1 is induced by both DNA and RNA viruses, including herpes simplex virus (HSV), influenza A virus (IAV), and Sendai virus (SeV). Mechanistically, ATP1B1 promotes antiviral innate immune responses by targeting TRAF3 and TRAF6 for ubiquitination, leading to enhanced activation of IRF3 and NF-κB signaling pathways and increased production of type I interferons (IFNs) and inflammatory cytokines.

The induction of ATP1B1 expression by viral infection is mediated through the NF-κB pathway, which binds to the *ATP1B1* promoter. This creates a positive feedback loop: viral infection activates NF-κB, which upregulates ATP1B1, which in turn enhances NF-κB signaling through TRAF6 ubiquitination, amplifying the antiviral response. This function of ATP1B1 is independent of its ion transport activity, as ion transport-deficient mutants retain the ability to enhance innate immune signaling.

### 3.6 Protein-Protein Interaction Network

The ATP1B1 protein participates in a complex network of protein-protein interactions. Key interaction partners include:

| **Interaction Partner** | **Function** | **Experimental Evidence** |
|---|---|---|
| ATP1A1 (α1 subunit) | Catalytic subunit of Na⁺/K⁺-ATPase | Co-immunoprecipitation, FRET |
| ATP1A2 (α2 subunit) | Catalytic subunit in muscle/glial cells | Co-immunoprecipitation |
| ATP1A3 (α3 subunit) | Catalytic subunit in neurons | Co-immunoprecipitation |
| E-cadherin (CDH1) | Adherens junction protein | Co-localization, co-IP |
| TRAF3 | E3 ubiquitin ligase, innate immune signaling | Co-IP, ubiquitination assays |
| TRAF6 | E3 ubiquitin ligase, NF-κB signaling | Co-IP, ubiquitination assays |
| SIK1 | Salt-inducible kinase, transcriptional regulation | Kinase assays, co-IP |
| CRTC1/CRTC2 | CREB coactivators | Indirect via SIK1 |
| HCMV UL136 | Viral protein, immune evasion | Yeast two-hybrid, co-IP |

The interaction with TRAF3 and TRAF6 is particularly significant, as it links ATP1B1 to the innate immune signaling network. The ubiquitination of TRAF3 and TRAF6 by ATP1B1 enhances their E3 ligase activity, promoting K63-linked polyubiquitination of downstream substrates and activating IRF3 and NF-κB signaling.

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Virus as "Viral Infection (HSV, IAV, SeV)"
    participant TLR as "TLR/RIG-I Receptors"
    participant NFkB as "NF-κB"
    participant ATP1B1 as "ATP1B1 Gene"
    participant TRAF as "TRAF3/TRAF6"
    participant IRF as "IRF3/NF-κB"
    participant IFN as "Type I IFNs & Cytokines"
    Virus->>TLR: Pathogen Recognition
    TLR->>NFkB: Activation
    NFkB->>ATP1B1: Transcriptional Activation
    ATP1B1->>TRAF: Protein Interaction & Ubiquitination
    TRAF->>IRF: K63-linked Ubiquitination
    IRF->>IFN: Enhanced Transcription
    IFN-->>Virus: Antiviral Response
    IFN-->>ATP1B1: Positive Feedback (via NF-κB)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

#### 4.1.1 Clear Cell Renal Cell Carcinoma (ccRCC)

In ccRCC, *ATP1B1* is frequently silenced through promoter hypermethylation rather than somatic mutation. Selvakumar et al. demonstrated that the *ATP1B1* promoter is hypermethylated in ccRCC cell lines and primary tumors, leading to loss of expression. This epigenetic silencing is associated with:
- Loss of cell adhesion
- Increased cell motility and invasion
- Activation of EMT programs
- Poor clinical outcomes

The tumor suppressor function of ATP1B1 in ccRCC is mediated through both its ion transport-dependent and -independent functions. Restoration of ATP1B1 expression in ccRCC cells suppresses tumor growth and metastasis in xenograft models.

#### 4.1.2 Diffuse Large B-Cell Lymphoma (DLBCL)

Copy number variations (CNVs) in *ATP1B1* have been identified as key drivers in DLBCL. Zhang et al. performed an integrative analysis of CNV and gene expression data and identified *ATP1B1* as a copy number driver gene in DLBCL. The study found that:
- *ATP1B1* is located in a recurrently amplified region on chromosome 1q
- Amplification is associated with increased mRNA expression
- High *ATP1B1* expression is associated with poor prognosis
- *ATP1B1* may serve as a potential therapeutic target in DLBCL

This finding is paradoxical given ATP1B1's tumor suppressor role in epithelial cancers, suggesting context-dependent functions. In DLBCL, ATP1B1 may promote tumor cell survival through its effects on ion homeostasis and cell volume regulation, which are critical for rapidly proliferating lymphocytes.

#### 4.1.3 Gastric Cancer and ATP1B1-NTRK1 Fusion

A novel *ATP1B1-NTRK1* fusion was identified in a case of gastric carcinoma. This fusion gene results from a chromosomal rearrangement that juxtaposes the *ATP1B1* promoter and N-terminal sequences with the *NTRK1* kinase domain. The fusion protein exhibits constitutive NTRK1 kinase activity, driving oncogenic signaling through the MAPK and PI3K-AKT pathways. This finding is significant because:
- It represents the first reported case of gastric carcinoma with NTRK rearrangement
- NTRK fusions are actionable targets for FDA-approved drugs (e.g., larotrectinib, entrectinib)
- The *ATP1B1* promoter may drive high-level expression of the fusion oncogene

#### 4.1.4 Breast Cancer

*ATP1B1* is located on chromosome 1q, a region frequently amplified in breast cancer. Bera et al. conducted integrative genomic analyses and identified *ATP1B1* among the genes on 1q that are differentially expressed in breast cancer. The clinical significance of *ATP1B1* in breast cancer is complex:
- Progesterone receptor (PR) signaling directly regulates *ATP1B1* expression
- Progestin-regulated miRNAs target *ATP1B1*, modulating its expression
- ATP1B1 overexpression enhances sensitivity to chemotherapy
- Loss of ATP1B1 is associated with EMT and metastasis

#### 4.1.5 Melanoma

Bioinformatic profiling of melanoma patients identified *ATP1B1* as part of a gene expression signature associated with prognosis and immunotherapy response. The study found that *ATP1B1* expression correlates with immune cell infiltration and may serve as a biomarker for immunotherapy efficacy.

### 4.2 Germline Polymorphisms and Hypertension

Multiple studies have investigated the association between *ATP1B1* polymorphisms and hypertension:

| **Polymorphism** | **Population** | **Association** | **Reference** |
|---|---|---|---|
| TRS in 3' UTR | Multi-ethnic | Blood pressure variation | |
| Multiple SNPs | African-American | Hypertension | |
| SNPs in intron 1 | Iraqi (CKD patients) | Hypertension with CKD | |
| RGS5/ATP1B1 haplotype | Chinese | Essential hypertension | |

The functional mechanism underlying the association between the TRS polymorphism and blood pressure involves alternative polyadenylation. The TRS element modulates the choice between proximal and distal polyadenylation signals, producing transcripts with different 3' UTR lengths. The long 3' UTR isoform contains binding sites for multiple miRNAs, including miR-192, which is involved in renal fluid balance. Differential miRNA binding leads to altered ATP1B1 expression levels, affecting Na⁺/K⁺-ATPase abundance in the kidney and ultimately influencing blood pressure.

### 4.3 Mutations Affecting Protein Function

While germline mutations in *ATP1B1* are rare, several pathogenic variants have been reported:

- **Missense mutations in the ectodomain**: Mutations affecting conserved cysteine residues (e.g., Cys⁸⁶Tyr) disrupt disulfide bond formation, leading to protein misfolding and ER retention. These mutations are predicted to cause complete loss of function.
- **Frameshift mutations in the transmembrane domain**: Insertions or deletions that disrupt the reading frame in exon 2 or 3 result in truncated proteins lacking the ectodomain. These are predicted to be null alleles.
- **Splice site mutations**: Mutations at the exon-intron boundaries can lead to exon skipping or intron retention, producing aberrant transcripts that are degraded by NMD.

The clinical phenotype associated with biallelic loss-of-function mutations in *ATP1B1* has not been fully characterized in humans, likely because complete loss of Na⁺/K⁺-ATPase function is embryonic lethal. However, heterozygous mutations may contribute to susceptibility to hypertension, renal dysfunction, and pulmonary edema.

### 4.4 Expression Changes in Other Diseases

#### 4.4.1 Cochlear Function and Hearing

*ATP1B1* is highly expressed in the human cochlea, where it contributes to the generation of the endocochlear potential and auditory nerve signaling. Liu and Rask-Andersen used mRNA in situ hybridization and super-resolution structured illumination microscopy to map Na/K-ATPase gene expression in the human cochlea, revealing high expression of *ATP1B1* in the stria vascularis and spiral ganglion neurons. Dysregulation of *ATP1B1* in the cochlea may contribute to hearing loss, particularly in conditions associated with altered ion homeostasis.

#### 4.4.2 Retinal Degeneration

In mice, knock-in of *Atp1b1* into the *Atp1b2* locus (Atp1b2^Atp1b1^ knock-in) results in a cone-rod dystrophy-like phenotype. Bartsch et al. demonstrated that the β1 subunit cannot fully compensate for the loss of β2 in the retina, leading to photoreceptor degeneration. This finding highlights the isoform-specific functions of β subunits in different tissues.

#### 4.4.3 Synovial Joint Development

*ATP1B1* expression is required for synovial joint cavitation during limb skeletogenesis. Koyama et al. showed that Na/K-ATPase ion pump expression and osmoregulatory activity are essential for the formation of joint cavities, with *ATP1B1* being a key component.

#### 4.4.4 Sperm Cryopreservation

*ATP1B1* expression is associated with the freezability of boar sperm. Mańkowska et al. found that mRNA and protein expression of *ATP1B1* differs between good and poor freezers, suggesting that ATP1B1 levels influence sperm cryotolerance.

#### 4.4.5 Diabetic Neuropathy

Single-cell RNA-seq analysis of dorsal root ganglia from diabetic rats with mechanical allodynia revealed altered expression of *ATP1B1* in specific cell populations. This suggests a potential role for ATP1B1 in the pathogenesis of diabetic peripheral neuropathy.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Cytomegalovirus (HCMV) UL136 Protein

A direct interaction between the HCMV UL136 protein and ATP1B1 has been demonstrated. Cui et al. used yeast two-hybrid screening and co-immunoprecipitation to show that UL136, a viral protein unique to the Toledo strain and low-passage clinical isolates, binds to ATP1B1. The functional consequences of this interaction include:
- Modulation of Na⁺/K⁺-ATPase activity
- Potential alteration of host cell ion homeostasis
- Possible effects on viral replication and spread

The UL136 protein is localized to the viral assembly complex and may hijack ATP1B1 to modify the host cell environment for optimal viral replication.

### 5.2 Antiviral Innate Immune Responses

As described in Section 3.5, ATP1B1 plays a critical role in antiviral innate immunity. The induction of ATP1B1 by viral infection and its enhancement of type I IFN responses through TRAF3/TRAF6 ubiquitination represent a novel host defense mechanism. This function is particularly relevant for:
- **Herpes simplex virus (HSV)**: ATP1B1 limits HSV replication by enhancing IFN responses
- **Influenza A virus (IAV)**: ATP1B1 restricts IAV replication
- **Sendai virus (SeV)**: ATP1B1 enhances SeV-induced IFN production

The antiviral function of ATP1B1 is independent of its ion transport activity, as demonstrated by experiments with ion transport-deficient mutants.

### 5.3 Other Viral Interactions

While direct interactions with other viral proteins have not been extensively characterized, the role of ATP1B1 in cell adhesion and membrane dynamics suggests it may be targeted by viruses that modulate cell-cell junctions for spread. Additionally, the Na⁺/K⁺-ATPase is a known target for several viral toxins and modulators, and ATP1B1 may be involved in these interactions.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Cardiac Glycosides

The Na⁺/K⁺-ATPase is the target of cardiac glycosides, including digoxin, digitoxin, and ouabain. These compounds bind to the α subunit and inhibit pump activity, increasing intracellular Na⁺ and Ca²⁺, which enhances cardiac contractility. While the β subunit is not the primary binding site for cardiac glycosides, it modulates the sensitivity of the holoenzyme to these drugs. The α1β1 isozyme is relatively resistant to cardiac glycosides compared to α2β1 and α3β1 isozymes, which has implications for tissue-specific drug effects.

### 6.2 Palytoxin

Palytoxin (PLTX), one of the most toxic natural compounds, targets the Na⁺/K⁺-ATPase. The sensitivity of cells to palytoxin correlates with the expression level of β subunit isoforms. Pelin et al. demonstrated that cells with high expression of the β2 subunit are more sensitive to palytoxin than those expressing β1. This differential sensitivity has implications for understanding the variable toxicity of palytoxin in different tissues and individuals.

### 6.3 Therapeutic Targeting in Cancer

#### 6.3.1 DLBCL

The identification of *ATP1B1* as a copy number driver gene in DLBCL suggests that it may be a therapeutic target. Strategies being explored include:
- **Small molecule inhibitors**: Compounds that inhibit Na⁺/K⁺-ATPase activity may be effective in DLBCL cells with ATP1B1 amplification
- **Antisense oligonucleotides (ASOs)**: Targeting *ATP1B1* mRNA to reduce expression
- **RNA interference (RNAi)**: siRNA or shRNA targeting *ATP1B1*

#### 6.3.2 Acute Myeloid Leukemia (AML)

Targeting the sodium-potassium pump has been proposed as a therapeutic strategy in AML. Schneider et al. identified the Na⁺/K⁺-ATPase as a selective dependency in AML cells, and demonstrated that cardiac glycosides have anti-leukemic activity. The β subunit composition may influence the sensitivity of AML cells to these agents.

#### 6.3.3 NTRK Fusion-Positive Cancers

The identification of the *ATP1B1-NTRK1* fusion in gastric cancer has therapeutic implications. NTRK fusion-positive cancers are sensitive to TRK inhibitors, including:
- **Larotrectinib**: FDA-approved for NTRK fusion-positive solid tumors
- **Entrectinib

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)